Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. - Wikidata - awgldk - TriplyDB

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q34146996

about

Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy Recent advances and novel treatment paradigms in acute lymphocytic leukemia New Therapeutic Strategies in Acute Lymphocytic Leukemia.Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome in de novo Philadelphia chromosome-negative precursor B-lineage acute lymphoblastic leukemia.Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia.Emerging pharmacotherapies for adult patients with acute lymphoblastic leukemia.Allogeneic hematopoietic cell transplantation for acute lymphoblastic leukemia in adults Joint Bayesian variable and graph selection for regression models with network-structured predictors Correlation between deletion of the CDKN2 gene and tyrosine kinase inhibitor resistance in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.CD5 Positive B Lymphoblastic Leukemia: Report of a Case with Review of Literature Therapy of Philadelphia chromosome-negative acute lymphoblastic leukemia in adults: new paradigms.Monoclonal antibody therapy with rituximab for acute lymphoblastic leukemia.A randomized controlled trial of an intensive insulin regimen in patients with hyperglycemic acute lymphoblastic leukemia.Treatment of acute lymphoblastic leukemia in adolescents and young adults.Optimal pharmacotherapeutic management of acute lymphoblastic leukaemia in the elderly.Antibody therapy for acute lymphoblastic leukemia.Criteria for and outcomes of allogeneic haematopoietic stem cell transplant in children, adolescents and young adults with acute lymphoblastic leukaemia in first complete remission.Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Novel targeted therapies in acute lymphoblastic leukemia.Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.Current status of antibody therapy in ALL.Future of Therapy in Acute Lymphoblastic Leukemia (ALL)--Potential Role of Immune-Based Therapies.Economic evaluation of rituximab in addition to standard of care chemotherapy for adult patients with acute lymphoblastic leukemia.Acute lymphoblastic leukemia: a comprehensive review and 2017 update Advances in adult acute lymphoblastic leukemia therapy.Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.Prognostic significance of immunophenotypic and karyotypic features of Philadelphia positive B-lymphoblastic leukemia in the era of tyrosine kinase inhibitors.Immunophenotypic markers in adult acute lymphoblastic leukemia: the prognostic significance of CD20 and TdT expression CD20 expression has no prognostic role in Philadelphia-negative B-precursor acute lymphoblastic leukemia: new insights from the molecular study of minimal residual disease.Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen Prognostic relevance of CD20 in adult B-cell precursor acute lymphoblastic leukemia High levels of CD20 expression predict good prognosis in chronic lymphocytic leukemia.Redefining transplant in acute leukemia.CD20 expression sub-stratifies standard-risk patients with B cell precursor acute lymphoblastic leukemia.Rituximab in the management of acute lymphoblastic leukemia.Current challenges and opportunities in treating adult patients with Philadelphia-negative acute lymphoblastic leukaemia.The ABCs of Immunotherapy for Adult Patients With B-Cell Acute Lymphoblastic Leukemia.

P2860

Q26745710-8B0D9FFC-ADB7-4652-8ED3-58C288B391AA Q28078076-0173C3D4-0442-4188-A336-175AF7A65DB6 Q30252776-7A3CA667-4067-411F-8986-30BFB42395EF Q33632278-0F9AE02D-D2F5-4F38-B838-A1026102063A Q34131844-D305FD19-4726-4661-A7FD-0A91F0869DDB Q35029453-C00E2418-4B59-49B1-BD9E-1FC5BA06217C Q35740894-F3AE2840-58F2-4C1B-AF56-5F1B966286D7 Q36461915-6E794D49-1C2D-457C-9036-555D414C96E5 Q36642833-02AE8B8E-8A6C-4C43-9E6F-3FFE4CDF4928 Q36811503-FB10587E-3D9D-4331-80A9-C7DEAC1FB96E Q37048334-1043FC11-3A25-475B-AF06-2850DE306C0F Q37605864-A23F98AA-F884-47C9-B80B-9CB39775C455 Q37613872-17F278FD-DC11-45EA-9794-8E1B973E307C Q37683288-E6D366E7-2620-43D3-BA5D-55AF556B00B5 Q37899785-0D8AF597-55F0-4DD1-B153-9F53D2B15F85 Q37931235-8978B954-6E16-4595-B394-2D7BDBAC5D3E Q37994136-C888139A-87D4-406C-BB93-EDB079BBBB85 Q38079288-6B2C570F-1DA0-41FE-89A3-CBFAEE4E4CA6 Q38094099-5D438498-DCFD-4E5C-83E6-B4843375A3EC Q38097334-EBBBB8E5-C8FB-4A14-AA32-1FBE8984C4C1 Q38120551-1DA862EB-8A24-4BAB-A65B-CE96E9E74FD8 Q38164108-797D3F6F-F972-4776-A7C7-2C4B9DDC5053 Q38224988-5F3FF3E1-40B6-47F9-82EC-4BB3B1F3362D Q38266338-40AD2385-2D14-4717-8328-8FD3FD11F5D8 Q38434000-0A7B155C-33AB-4672-9317-85AEA93A70C0 Q38610250-3CFC7FF4-4948-4518-B585-CBF7C6840F3D Q39406969-489EF883-A16D-4C88-B469-E5AFEF44C92F Q39459190-69DD1F72-59E0-4EA6-A446-45B96A783C42 Q40312849-DB801522-B511-4248-8F99-E353E579A02B Q41299717-122D2EDB-5047-42BF-BCBF-83C8E756EB63 Q41831328-6C7E1100-9119-4170-B0EB-2DA8E92B7EAA Q41839634-1B9ACC95-7867-4952-B995-AD538723F910 Q42634946-7388DDB7-A9E2-4203-8E4B-BCB25932BCF7 Q42765021-A712FA4D-9B77-45FF-BB99-505044D44E89 Q44521795-57C76C88-7AE8-45A7-A3BC-BAEB3A0DB988 Q44657508-2B098D55-6448-494F-8279-7C1F9D500D71 Q47145213-9EF98FC2-2610-40A5-BBA5-10DD1D47555A Q47196522-DFDF5DA4-2756-4B09-9FDE-B38B600BE50E Q47706549-DB4B0481-4045-4CD4-B5A5-91B407C62077 Q47809709-08C92226-05DF-4872-BFA8-3320A9481939

P2860

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia.

http://www.wikidata.org/entity/Q34146996

description

2008 nî lūn-bûn

@nan

2008 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

Prognostic significance of CD2 ...... acute lymphoblastic leukemia.

@ast

Prognostic significance of CD2 ...... acute lymphoblastic leukemia.

@en

Prognostic significance of CD2 ...... acute lymphoblastic leukemia.

@nl

type

label

Prognostic significance of CD2 ...... acute lymphoblastic leukemia.

@ast

Prognostic significance of CD2 ...... acute lymphoblastic leukemia.

@en

Prognostic significance of CD2 ...... acute lymphoblastic leukemia.

@nl

prefLabel

Prognostic significance of CD2 ...... acute lymphoblastic leukemia.

@ast

Prognostic significance of CD2 ...... acute lymphoblastic leukemia.

@en

Prognostic significance of CD2 ...... acute lymphoblastic leukemia.

@nl

P1433

Q34146996-EDD345CE-D704-46F3-BB62-6D3FFEFBD885

P1476

Q34146996-F5173C7F-B54F-433E-AB3C-8F1D4DD8C1A1

P2093

Q34146996-5C8F4A08-6657-4DC3-B04B-4279FF8DC0EB

Q34146996-A4665F21-9D11-4C85-9C03-96071D49BF3E

Q34146996-B50D11AF-C9AB-4473-ADFB-1650E9A1330B

Q34146996-F78B811B-FFF0-467E-9387-B3F4C8B6EDD6

P2860

Q34146996-0B3E7B64-A0BA-4725-83AF-6F950CE6964A

Q34146996-1F9D4FDB-27A8-4F50-9103-ADF1039AA74F

Q34146996-3D3C3C62-615D-4145-B4A5-D347A55BF6AC

Q34146996-49FC596A-A5B7-434A-9422-CCDA9927D7C0

Q34146996-5A86C55C-81BA-457B-A51D-90E7B073E926

Q34146996-7C50888C-93B9-4AC2-9E97-7F2FFD07948E

Q34146996-97F74786-CB78-44A3-956F-34A54F8F3D9A

Q34146996-A6CDC383-E20A-4103-9B3F-30AE4F7B4E5A

Q34146996-CDA1518C-2113-47A6-A1DC-FEB634876CA7

Q34146996-D46D7ACB-2D4C-4949-9E25-E28DE0BDC573

P304

Q34146996-AD1FB341-4E4E-4FDD-9676-58EAAA8B654C

P31

Q34146996-5DA06C84-F6E3-4C62-B3F6-58C88450974B

P356

Q34146996-6A66D88D-203B-49BC-846D-5A9C02DBC461

P407

Q34146996-AEB2A60F-698C-4D8E-99A3-B6BC7DF585FB

P433

Q34146996-E95C32F5-BE93-43FD-A5CD-53698D27636C

P478

Q34146996-CD31CED5-C2A0-4D4D-A3FC-7226CEB4F673

P50

Q34146996-0457BC2D-204F-487D-BEB3-5E146195AFF4

Q34146996-2A3EDBBE-78F9-4CD3-9D7F-C04314CD84C7

Q34146996-316DD01A-0203-46F3-94A8-8E7B0A57A70C

Q34146996-3D962BD4-8F56-4583-9AE8-0C420FA0F52F

Q34146996-46ED3844-57FF-4F1D-98A9-E7485C9E77AA

Q34146996-8571786D-A952-4335-BBEC-12ED10AE2012

Q34146996-A96F3922-0C92-441A-B987-E668D32DBC87

Q34146996-F0A94A28-24B9-4894-8715-BD2DB31AD0B9

Q34146996-F94C8E2A-F42C-46A5-9B2E-2CD0E6B459DE

P577

Q34146996-851B0694-5DF6-48C3-8E2A-054E3EF559A3

P5875

Q34146996-C511B0B5-45FA-44AF-B1E7-1BCA0EB47091

P698

Q34146996-50A2DEC7-ED31-4386-AB3D-588EC103DB53

P921

Q34146996-5C093B36-B80D-4CC4-B261-70955D1C021E

P932

Q34146996-BF4C9A5B-03B4-40E5-8377-C94A1FDB7D90

P356

BLOOD-2008-04-151860

P1433

P1476

Prognostic significance of CD2 ...... acute lymphoblastic leukemia.

@en

P2093

Charles Koller

http://www.w3.org/2001/XMLSchema#string

Deborah A Thomas

http://www.w3.org/2001/XMLSchema#string

Jeffrey L Jorgensen

http://www.w3.org/2001/XMLSchema#string

Yang Huh

http://www.w3.org/2001/XMLSchema#string

P2860

Evaluation of survival data and two new rank order statistics arising in its consideration.

Rituximab in relapsed or refractory hairy cell leukemia.

Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia.

Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia.

Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia.

Philadelphia chromosome positive acute lymphocytic leukemia: a new era of challenges.

Update of the M. D. Anderson Cancer Center experience with hyper-CVAD and rituximab for the treatment of mantle cell and Burkitt-type lymphomas.

Levels of expression of CD19 and CD20 in chronic B cell leukaemias.

Acquirement of rituximab resistance in lymphoma cell lines is associated with both global CD20 gene and protein down-regulation regulated at the pretranscriptional and posttranscriptional levels.

Development of rituximab-resistant lymphoma clones with altered cell signaling and cross-resistance to chemotherapy.

P304

6330-6337

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2008-04-151860

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

113

http://www.w3.org/2001/XMLSchema#string

P50

Jorge Eduardo Cortes

Hagop Kantarjian

William G Wierda

Srdan Verstovsek

Guillermo Garcia-Manero

Michael J. Keating

P577

2008-08-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23171396

http://www.w3.org/2001/XMLSchema#string

P698

18703706

http://www.w3.org/2001/XMLSchema#string

P921

P932

2943753

http://www.w3.org/2001/XMLSchema#string